- Home
- NVCR vs YDES Comparison
NVCR vs YDES Comparison
Compare NVCR & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- YDES
- Stock Information
- Founded
- NVCR 2000
- YDES 2013
- Country
- NVCR Switzerland
- YDES Taiwan
- Employees
- NVCR N/A
- YDES N/A
- Industry
- NVCR Medical/Dental Instruments
- YDES
- Sector
- NVCR Health Care
- YDES
- Exchange
- NVCR Nasdaq
- YDES Nasdaq
- Market Cap
- NVCR 1.3B
- YDES 1.1B
- IPO Year
- NVCR 2015
- YDES N/A
- Fundamental
- Price
- NVCR $11.25
- YDES $11.03
- Analyst Decision
- NVCR Buy
- YDES
- Analyst Count
- NVCR 7
- YDES 0
- Target Price
- NVCR $28.64
- YDES N/A
- AVG Volume (30 Days)
- NVCR 1.5M
- YDES 81.1K
- Earning Date
- NVCR 10-30-2025
- YDES 09-30-2025
- Dividend Yield
- NVCR N/A
- YDES N/A
- EPS Growth
- NVCR N/A
- YDES N/A
- EPS
- NVCR N/A
- YDES N/A
- Revenue
- NVCR $642,269,000.00
- YDES $510,360.00
- Revenue This Year
- NVCR $9.54
- YDES N/A
- Revenue Next Year
- NVCR $5.70
- YDES N/A
- P/E Ratio
- NVCR N/A
- YDES N/A
- Revenue Growth
- NVCR 11.17
- YDES 45.76
- 52 Week Low
- NVCR $10.70
- YDES $5.30
- 52 Week High
- NVCR $34.13
- YDES $31.00
- Technical
- Relative Strength Index (RSI)
- NVCR 35.05
- YDES N/A
- Support Level
- NVCR $10.70
- YDES N/A
- Resistance Level
- NVCR $12.01
- YDES N/A
- Average True Range (ATR)
- NVCR 0.57
- YDES 0.00
- MACD
- NVCR -0.11
- YDES 0.00
- Stochastic Oscillator
- NVCR 15.48
- YDES 0.00
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.